Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026
Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Fineline Cube Jul 3, 2026
Company Deals

CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China

Fineline Cube Mar 25, 2025

Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an...

Company Drug

AllianThera Biopharma Starts Global Phase I Trial for ATB102 in Inflammatory Bowel Diseases

Fineline Cube Mar 24, 2025

Suzhou-based startup AllianThera Biopharma has announced the first patient dosing in a global Phase I...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Ivarmacitinib Receives NMPA Approval for Ankylosing Spondylitis

Fineline Cube Mar 24, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving marketing approval from the National...

Company Medical Device

Oriomics’ Liver Cancer Screening Reagent Earns FDA Breakthrough Device Designation

Fineline Cube Mar 24, 2025

Hangzhou-based Oriomics, a cancer screening specialist backed by Hotgen Biotech Co., Ltd (SHA: 688068), has...

Company Deals Drug

Kexing Biopharm Partners with BioMap on AI-Driven Macromolecular Drug Development

Fineline Cube Mar 24, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with US biotech firm BioMap...

Company Drug

CStone Pharmaceuticals Files for EMA Approval of Sugemalimab for Unresectable Stage III NSCLC

Fineline Cube Mar 24, 2025

China-based CStone Pharmaceuticals (HKG: 2616) has announced filing for another indication approval for its anti-programmed...

Company Deals

Abbisko Therapeutics and Allist Pharmaceuticals Partner on KRAS-G12C NSCLC Combination Therapy

Fineline Cube Mar 24, 2025

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has entered into a cooperation agreement with...

Company

Eli Lilly Launches Lilly Gateway Laboratory in China to Boost Biotech Innovation

Fineline Cube Mar 24, 2025

US major Eli Lilly & Co., (NYSE: LLY) has announced the opening of the Lilly...

Company Drug

Clover Biopharmaceuticals Receives FDA Approval for SCB-1019 RSV Vaccine Trial

Fineline Cube Mar 24, 2025

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced receiving clinical approval from the US Food...

Company Drug

AIM Vaccine’s mRNA-based Shingles Vaccine Receives FDA Approval for Clinical Study

Fineline Cube Mar 24, 2025

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the US Food...

Medical Device Policy / Regulatory

NMPA Updates Rules on Domestic Production of Imported Medical Devices

Fineline Cube Mar 24, 2025

The National Medical Products Administration (NMPA) has released a notification on further adjusting and optimizing...

Company Medical Device

Broncus Medical’s BroncQCT Approved by Zhejiang Administration for China Market Entry

Fineline Cube Mar 24, 2025

Broncus Medical Inc., a provider of precision intervention solutions for lung diseases with operations in...

Company Medical Device

Lifetech Scientific’s LAmbre Plus LAA Closure System Gains US Medical Insurance Coverage

Fineline Cube Mar 24, 2025

China-based Lifetech Scientific Corporation (HKG: 1302) has announced obtaining medical insurance coverage in the United...

Company

Hansoh Pharmaceutical Reports 21% Revenue Growth, Boosted by Innovative Drugs

Fineline Cube Mar 24, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) released its 2024 financial report last week,...

Company

Johnson & Johnson Pledges USD55 Billion for US Expansion, Focusing on Manufacturing and R&D

Fineline Cube Mar 24, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) has committed to investing over USD 55...

Company Drug

FDA Issues Second CRL to Hengrui’s Camrelizumab Combo Due to Manufacturing Issues

Fineline Cube Mar 24, 2025

The US Food and Drug Administration (FDA) last week issued another complete response letter (CRL)...

Company Legal / IP

AbbVie Sues Genmab Over Alleged Trade Secret Misappropriation in ADC Development

Fineline Cube Mar 24, 2025

US pharmaceutical giant AbbVie (NYSE: ABBV) has filed a lawsuit in the U.S. District Court...

Company Drug

Shanghai Junshi Biosciences’ Loqtorzi Approved for Hepatocellular Carcinoma Treatment

Fineline Cube Mar 24, 2025

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced receiving approval from the...

Company Legal / IP

Shanghai Pharmaceuticals Subsidiary Fined USD23 Million for Anti-Monopoly Violations

Fineline Cube Mar 24, 2025

China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) has disclosed that its subsidiary, Shanghai SINE...

Company Drug

HutchMed’s Tazverik Receives Conditional Approval from China’s NMPA for Lymphoma Treatment

Fineline Cube Mar 24, 2025

China-based HutchMed (NASDAQ: HCM, HKG: 0013) has announced receiving conditional marketing approval from the National...

Posts pagination

1 … 215 216 217 … 690

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.